Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Current Leases (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Current Leases for 7 consecutive years, with $6.2 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 37.42% to $6.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.2 million through Dec 2025, up 37.42% year-over-year, with the annual reading at $6.2 million for FY2025, 37.42% up from the prior year.
  • Current Leases hit $6.2 million in Q4 2025 for BridgeBio Pharma, up from $5.3 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $6.2 million in Q4 2025 to a low of $3.7 million in Q1 2023.
  • Historically, Current Leases has averaged $4.5 million across 5 years, with a median of $4.5 million in 2021.
  • Biggest five-year swings in Current Leases: soared 51.67% in 2021 and later fell 25.58% in 2022.
  • Year by year, Current Leases stood at $4.9 million in 2021, then dropped by 25.58% to $3.7 million in 2022, then increased by 12.33% to $4.1 million in 2023, then increased by 9.16% to $4.5 million in 2024, then soared by 37.42% to $6.2 million in 2025.
  • Business Quant data shows Current Leases for BBIO at $6.2 million in Q4 2025, $5.3 million in Q3 2025, and $4.8 million in Q2 2025.